Genentech product inventories
Wholesaler inventories of Rituxan and Herceptin were on "the higher end" of the typical range at the end of Q4 and "at the lower end of the typical range by the end of March," COO Myrtle Potter says April 9. Exec stands by earlier comments that inventory buildups did not contribute to strong Q4 performance. Firm says it closely monitors inventory and has internal processes in place to eliminate speculative buying (1"The Pink Sheet" April 15, 2002, p. 27); price increases for Herceptin, Rituxan became effective in early March but did not impact first quarter results...
You may also be interested in...
Genentech has effectively eliminated speculative buying by drug wholesalers in advance of price increases, Exec VP-Commercial Operations Myrtle Potter declared in an April 9 analyst call
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.